David Mcerlane Sells 1,994 Shares of Catalent, Inc. (NYSE:CTLT) Stock

Catalent, Inc. (NYSE:CTLT) insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Catalent Price Performance

Shares of CTLT stock traded down $0.08 on Friday, reaching $60.21. 440,001 shares of the company were exchanged, compared to its average volume of 2,100,392. Catalent, Inc. has a 1 year low of $31.80 and a 1 year high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The business has a 50-day moving average price of $59.64 and a 200 day moving average price of $57.31. The company has a market cap of $10.90 billion, a price-to-earnings ratio of -9.88, a P/E/G ratio of 2.32 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. Equities research analysts forecast that Catalent, Inc. will post 0.85 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Catalent during the second quarter worth about $29,172,000. Sanctuary Advisors LLC purchased a new position in Catalent in the 2nd quarter worth approximately $208,000. Truist Financial Corp boosted its holdings in shares of Catalent by 37.2% during the 2nd quarter. Truist Financial Corp now owns 28,029 shares of the company’s stock worth $1,576,000 after purchasing an additional 7,600 shares during the last quarter. Millennium Management LLC grew its position in shares of Catalent by 129.2% in the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares in the last quarter. Finally, MBB Public Markets I LLC acquired a new stake in shares of Catalent in the second quarter valued at approximately $788,000.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Baird R W lowered Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Robert W. Baird reissued a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday. Barclays lifted their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. Royal Bank of Canada reissued a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. According to MarketBeat.com, Catalent currently has a consensus rating of “Hold” and an average target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.